18/09/2024
|
07:00
|
Interim results for the six months to 30 June 2024
|
RNS
|
12/08/2024
|
13:28
|
Holding(s) in Company
|
RNS
|
26/07/2024
|
07:00
|
Voluntary Delisting from OTCQB Market
|
RNS
|
10/07/2024
|
07:00
|
Notification of Major Holdings
|
RNS
|
02/07/2024
|
07:00
|
Change of Registered Address
|
RNS
|
17/06/2024
|
08:38
|
Result of AGM
|
RNS
|
09/05/2024
|
07:00
|
Annual Report & AGM Notice
|
RNS
|
01/05/2024
|
07:00
|
Significant POLB 001 Patent Granted in USA
|
RNS
|
30/04/2024
|
07:02
|
Appointment of Joint Broker
|
RNS
|
30/04/2024
|
07:00
|
Results for the year ended 31 December 2023
|
RNS
|
30/04/2024
|
07:01
|
Option Agreement to Acquire Orphan Drug Candidate
|
RNS
|
29/04/2024
|
07:00
|
TR-1: Notification of major holdings
|
RNS
|
22/02/2024
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
19/02/2024
|
13:42
|
Director Share Purchase
|
RNS
|
15/02/2024
|
07:00
|
Board Role Change and Launch of EIP
|
RNS
|
17/01/2024
|
07:00
|
Further data shows POLB001 potential in cancer CRS
|
RNS
|
20/12/2023
|
07:00
|
RSV AI Drug Candidate Analysis Update
|
RNS
|
11/12/2023
|
07:00
|
POLB 001 Data Presented at ASH
|
RNS
|
30/11/2023
|
07:00
|
Directorate Change
|
RNS
|
09/11/2023
|
07:00
|
Former Amryt Pharma Leadership Team join Poolbeg
|
RNS
|
03/11/2023
|
07:05
|
POLB001 Data to be Presented at ASH Annual Meeting
|
RNS
|
01/11/2023
|
07:00
|
POLB 001 Oncology Programme Update Meeting
|
RNS
|
17/10/2023
|
07:00
|
Poolbeg Partners with a Nasdaq-Listed Biopharma
|
RNS
|
29/09/2023
|
07:00
|
Favourable Conclusion of Patent Opposition
|
RNS
|
19/09/2023
|
07:00
|
Immunomodulator I Patent Opposition Withdrawal
|
RNS
|
13/09/2023
|
07:00
|
Interim results for the six months to 30 June 2023
|
RNS
|
29/06/2023
|
07:00
|
AI led programme identifies influenza drug targets
|
RNS
|
22/06/2023
|
07:00
|
Oral Vaccine Programme Moves Forward
|
RNS
|
24/05/2023
|
07:00
|
Board Appointment
|
RNS
|
11/05/2023
|
14:27
|
Results of Annual General Meeting
|
RNS
|
12/04/2023
|
07:00
|
Annual Report & AGM Notice
|
RNS
|
30/03/2023
|
07:00
|
Results for the year ended 31 December 2022
|
RNS
|
10/03/2023
|
07:00
|
Notification of Major Holdings
|
RNS
|
09/03/2023
|
15:51
|
Notification of Major Holdings
|
RNS
|
02/03/2023
|
11:05
|
Second Price Monitoring Extn
|
RNS
|
02/03/2023
|
11:00
|
Price Monitoring Extension
|
RNS
|
02/03/2023
|
07:00
|
Positive Results POLB001 LPS Human Challenge Trial
|
RNS
|
16/01/2023
|
07:00
|
Strategic expansion of POLB 001 into oncology
|
RNS
|
09/01/2023
|
09:05
|
Second Price Monitoring Extn
|
RNS
|
09/01/2023
|
09:00
|
Price Monitoring Extension
|
RNS
|
09/01/2023
|
07:00
|
Positive Initial Data Analysis in POLB 001 Trial
|
RNS
|
22/12/2022
|
10:48
|
Poolbeg Pharma identifies new RSV drug candidates
|
EQS Group
|
21/12/2022
|
07:00
|
Poolbeg identifies novel RSV drug candidates
|
RNS
|
15/12/2022
|
09:49
|
Poolbeg Pharma makes 'interesting addition to existing collaboration'
|
EQS Group
|
14/12/2022
|
07:00
|
Metabolic diseases oral delivery licence signed
|
RNS
|
12/12/2022
|
14:05
|
Second Price Monitoring Extn
|
RNS
|
12/12/2022
|
14:00
|
Price Monitoring Extension
|
RNS
|
12/12/2022
|
12:00
|
Poolbeg Pharma receives initial results from human challenge clinical study
|
EQS Group
|
12/12/2022
|
07:00
|
POLB 001 LPS human challenge trial completed
|
RNS
|
21/11/2022
|
11:37
|
Poolbeg Pharma wins first non-dilutive grant funding
|
EQS Group
|